An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01676922

Enrollment

256

Registered

2012-08-31

Start date

2011-08-31

Completion date

2015-05-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/ 70 years of age * Previously untreated metastatic colorectal cancer * Patient considered suitable to receive chemotherapy with or without Avastin

Exclusion criteria

* Participation in any other clinical trial or study with the exception of participation in registries

Design outcomes

Primary

Measure	Time frame
Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice	approximately 24 months

Secondary

Measure	Time frame
Clinical/demographic patient characteristics at baseline	approximately 24 months
Treatment duration in patients receiving chemotherapy alone as first-line therapy in daily clinical practice	approximately 24 months
Safety: Incidence of adverse events/adverse events of special interest	approximately 24 months
Dosage/regimen	approximately 24 months
Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment	approximately 24 months

Countries

Belgium

Outcome results